Health News Releases

  • Today November 13
December 01, 2016 11:35
Takeda to Invest More Than 100 Million Euros in Dengue Vaccine Manufacturing Plant in Germany
Takeda Pharmaceutical Company Limited (TOKYO:4502) (“Takeda”) today announced that it will invest more than 100 Million Euros to build a new manufacturing plant for its dengue vaccine candidate in Sin
November 30, 2016 17:10
Patient Safety Movement Foundation Names Dr. Jannicke Mellin-Olsen to Its Board of Directors
The Patient Safety Movement Foundation (PSMF) has named long-time patient safety advocate Jannicke Mellin-Olsen, MD, DPH, to its Board of Directors. In addition to her full-time clinical post in Bærum
November 29, 2016 09:45
Boehringer Ingelheim and China Southeast University collaborate to develop new treatment approaches for hearing loss
Boehringer Ingelheim and China Southeast University Institute of Life Sciences today announced the start of a joint research project to develop new treatment approaches for hearing loss through regene
November 28, 2016 17:20
NINLARO™ (ixazomib) Receives Conditional Approval from the European Commission to Treat Multiple Myeloma
Takeda Pharmaceutical Company Limited (TSE: 4502) today announced that the European Commission has granted conditional marketing authorization for NINLARO™ (ixazomib) capsules, indicated in combinatio
November 17, 2016 09:55
Boehringer Ingelheim welcomes central role of LAMA/LABA therapy within 2017 GOLD Strategy for COPD
Boehringer Ingelheim welcomes the updated 2017 Global Initiative for Chronic Obstructive Lung Disease (GOLD) Strategy which now positions a combination of a LAMA (long-acting anticholinergic) and a LA
November 17, 2016 09:50
Updated Phase III Results Reinforce Safety and Efficacy of Praxbind® (idarucizumab) in Urgent Situations
Boehringer Ingelheim announced updated results from data for 494 patients participating in the ongoing phase III RE-VERSE AD™ study, which showed that administration of 5g of idarucizumab immediately
November 16, 2016 13:45
Gore Global Registry for Endovascular Aortic Treatment Completes Enrollment
W. L. Gore & Associates, Inc. (Gore) today announced at the VEITHsymposium®, the completion of target enrollment in the Global Registry for Endovascular Aortic Treatment (GREAT). More than 5,000 patie
November 15, 2016 17:45
Bioventus Expands to Mexico with DUROLANE® for Knee Osteoarthritis Patients
Bioventus, a leader in orthobiologic solutions, has entered the patient care market in Mexico. This announcement reflects the company’s continued growth in international markets and its mission to par
November 15, 2016 14:00
Data on Early Onset of Efficacy for Oral OTEZLA® (apremilast) in Active Psoriatic Arthritis Presented at American College of Rheumatology
Celgene Corporation (NASDAQ: CELG) today announced findings from the ACTIVE phase 3b clinical trial of OTEZLA® (apremilast), the Company's oral, selective inhibitor of phosphodiesterase 4 (PDE4), at t
November 15, 2016 13:55
Jardiance® (empagliflozin) consistently reduced the risk of cardiovascular death in adults with type 2 diabetes regardless of the type of cardiovascular disease at baseline
New data presented at the American Heart Association Scientific Sessions 2016 showed that Jardiance® (empagliflozin) consistently reduced the risk for cardiovascular death, regardless of the type of c
November 14, 2016 17:05
New landmark study reveals adults with diabetes at unnecessary risk of vision loss
Despite vision loss being feared twice as much as other common complications of diabetes (including cardiovascular disease and stroke) a quarter of people with diabetes surveyed are not discussing eye
November 14, 2016 14:20
Masimo Receives Gates Foundation Grant to Develop Combined Pneumonia-Screening Device for High-Burden Settings
Masimo (NASDAQ: MASI) announced today, in advance of World Pneumonia Day tomorrow, that it has received a grant of $4.95 million from the Bill & Melinda Gates Foundation (BMGF). The grant will support
November 14, 2016 11:30
Patient enrolment completed for RE-DUAL PCI™ study assessing dabigatran in atrial fibrillation patients after PCI with stenting
Patient enrolment into the international Phase IIIb RE-DUAL PCI™ study is complete.[1] The study evaluates the safety and efficacy of dabigatran etexilate (marketed as Pradaxa®) in atrial fibrillation
November 09, 2016 15:50
Adare Pharmaceuticals Appoints Dr. Peter Richardson as Vice President, Research & Development and Chief Medical Officer
Adare Pharmaceuticals, Inc. announced that Dr. Peter Richardson has joined the Company as Vice President, Research & Development and Chief Medical Officer. Dr. Richardson will be responsible for leadi
November 09, 2016 15:10
Bioventus Appoints Andrew McCartney Managing Director, International for EMEA
Bioventus, a global leader in orthobiologic solutions, today announced the appointment of Andrew McCartney as Managing Director, International for Europe, Middle East and Africa (EMEA). McCartney, who
November 09, 2016 11:20
Seattle Genetics and Takeda Complete Enrollment of Phase 3 ECHELON-2 Clinical Trial Evaluating ADCETRIS® (Brentuximab Vedotin) in Frontline Mature T-cell Lymphoma
Seattle Genetics, Inc. (Nasdaq: SGEN) and Takeda Pharmaceutical Company Limited (TSE:4502) today announced completion of patient enrollment in the ECHELON-2 clinical trial. ECHELON-2 is a global phase
November 08, 2016 18:15
New European study highlights differing priorities in physician’s therapy goals when treating advanced lung cancer patients
Results from a survey analysing the prescribing behaviour of 500 European physicians treating patients with advanced non-small cell lung cancer (NSCLC) have been published in Clinical Lung Cancer. The
November 08, 2016 14:20
Philips and Masimo Sign Multi-Year Business Partnership Agreement in Patient Monitoring and Select Therapy Solutions
Royal Philips (NYSE: PHG; AEX: PHIA) and Masimo Corporation (NASDAQ: MASI) today announced a wide-ranging, multi-year business partnership involving both companies’ innovations in patient monitoring a
November 07, 2016 11:20
New Children’s Health Products Sell Out at Mannatech’s Asia MannaFest℠ 2016 Event
Mannatech®, Incorporated (NASDAQ: MTEX), a global health and wellness company committed to changing lives to make a better world, sold out its pre-order of two newly launched children’s health product
November 04, 2016 10:15
Takeda to Present Broad Range of Clinical Data During 58th American Society of Hematology Annual Meeting
Takeda Pharmaceutical Company Limited (TSE: 4502) today announced that it will present a total of 16 company-sponsored abstracts at the 58th American Society of Hematology (ASH) Annual Meeting taking
November 03, 2016 17:05
Medtronic Signs the “Open Data Pledge” to Share Data to Improve Patient Safety
The Patient Safety Movement Foundation (PSMF) today announced that Medtronic, a leading global healthcare solutions company, has joined a growing list of healthcare technology companies that have sign
November 02, 2016 18:00
Takeda Donates 1 Billion Yen as an Exclusive Partner to the United Nations Foundation for “Global Measles Vaccination for Children” Program
Takeda Pharmaceutical Company Limited (TOKYO:4502) today announced that Takeda will exclusively support “Global Measles Vaccination for Children” by the United Nations Foundation’s Shot@Life campaign.
November 02, 2016 17:45
Takeda: CSR Programs Focusing on Maternal and Child Health
Takeda Pharmaceutical Company Limited (TOKYO:4502) today announced that the company will implement three CSR programs focusing on solutions to maternal and child healthcare problems in Africa and Asia
November 02, 2016 11:05
Overall survival data from LUX-Lung 7 head-to-head trial of afatinib versus gefitinib presented at ESMO 2016
Boehringer Ingelheim today announced results from the LUX-Lung 7 trial that directly compared the efficacy and safety of second-generation EGFR-directed therapy afatinib* (Giotrif®) and first-generati
October 31, 2016 10:25
Takeda Reports First Half FY2016 Results and Raises Full Year Profit Guidance
Takeda Pharmaceutical Company Limited (TOKYO:4502): Strong first half results led by Growth Drivers · Underlying Revenue grew +7.4%, led by a +15.3% increase of Takeda's Growth Drivers (GI, Onc
25 per page50 per page75 per page100 per page